LZAGF - Lonza Group Ltd
| Previous close | 631.60 |
| Open | 630.82 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's range | 621.65 - 630.82 |
| 52-week range | 439.65 - 673.62 |
| Volume | |
| Avg. volume | 279 |
| Market cap | 46.989B |
| Beta (5Y monthly) | 0.62 |
| PE ratio (TTM) | 34.79 |
| EPS (TTM) | 18.04 |
| Earnings date | N/A |
| Forward dividend & yield | 3.94 (0.63%) |
| Ex-dividend date | 09 May 2023 |
| 1y target est | N/A |
Simply Wall St.Individual investors account for 56% of Lonza Group AG's (VTX:LONN) ownership, while institutions account for 44%
Key Insights Significant control over Lonza Group by individual investors implies that the general public has more...
- EQS Group
Q1 2023 Qualitative Update: Business Performance In Line With Full-Year Trajectory
Lonza Group AG / Key word(s): Quarter Results10-May-2023 / 07:00 CET/CESTRelease of an ad hoc announcement pursuant to Art. 53 LRThe issuer is solely responsible for the content of this announcement.Ad hoc announcement pursuant to Art. 53 LR Robust commercial demand, with softer early-stage demand due to biotech funding constraints Growth project portfolio progressing in line with plan Outlook 2023 reiterated, with high single-digit CER sales growth and CORE EBITDA margin of 30 to 31%Basel, Swit
- EQS Group
Lonza Announces Results of the 2023 Annual General Meeting – All Motions Proposed by Board of Directors Accepted
Lonza Group AG / Key word(s): AGMEGMLonza Announces Results of the 2023 Annual General Meeting – All Motions Proposed by Board of Directors Accepted 05.05.2023 / 15:00 CET/CEST Shareholders re-elected all existing members of the Board of Directors Albert M. Baehny was re-elected as Chairman of the Board of Directors A dividend of CHF 3.50 per share will be paid out starting from 11 May 2023 Attending and represented shareholders collectively held a total of 46,482,431 shares, representing 62.42%
- Simply Wall St.
Does Lonza Group (VTX:LONN) Deserve A Spot On Your Watchlist?
Investors are often guided by the idea of discovering 'the next big thing', even if that means buying 'story stocks...
- EQS Group
Lonza Increases Straight Bond by CHF 150 Million
Lonza Group AG / Key word(s): Bond/FinancingLonza Increases Straight Bond by CHF 150 Million 20.04.2023 / 18:30 CET/CESTBasel, Switzerland, 20 April 2023 – Lonza Swiss Finance Ltd, a wholly owned company of Lonza Group Ltd, Basel (“Lonza”), announced today the increase of the Straight Bond issued on 8 February 2023 by CHF 150 million, in line with its financing plan for 2023. The increment has the same maturity (6.5 years) and coupon (2.100%) as the initial issuance. The issuer is Lonza Swiss Fi
- Simply Wall St.
Lonza Group's (VTX:LONN) five-year earnings growth trails the impressive shareholder returns
The most you can lose on any stock (assuming you don't use leverage) is 100% of your money. But on a lighter note, a...
- EQS Group
Lonza Launches Share Buyback Program of up to CHF 2 Billion
Lonza Group AG / Key word(s): Corporate ActionLonza Launches Share Buyback Program of up to CHF 2 Billion 31.03.2023 / 07:00 CET/CESTBasel, Switzerland, 31 March 2023 – On 3 April 2023, Lonza will launch a share buyback program of up to CHF 2 billion, as announced on 25 January 2023. Enabled by Lonza’s strong balance sheet and positive outlook, the share buyback program aims to return excess capital to shareholders without impacting the company’s capability to invest in organic growth and bolt-o
- EQS Group
Lonza Completes Clinical and Commercial Drug Product Manufacturing Line in Visp (CH)
Lonza Group AG / Key word(s): ExpansionLonza Completes Clinical and Commercial Drug Product Manufacturing Line in Visp (CH) 29.03.2023 / 09:00 CET/CEST Lonza increases capacity and capabilities in Visp (CH) with the completion of a new line for cGMP clinical and commercial drug product manufacturing The line is fully operational, and the first customer batches will be filled in April 2023 This expansion follows the groundbreaking of a large-scale commercial drug product facility in Stein (CH), i
- EQS Group
Lonza Publishes Invitation to the 2023 Annual General Meeting and 2022 Annual and Sustainability Reports
Lonza Group AG / Key word(s): AGMEGM27-March-2023 / 07:00 CET/CESTRelease of an ad hoc announcement pursuant to Art. 53 LRThe issuer is solely responsible for the content of this announcement.Ad hoc announcement pursuant to Art. 53 LR Annual General Meeting to take place on 5 May 2023 at the Congress Center in Basel, Switzerland Albert M. Baehny proposed for re-election as Chairman of the Board of Directors, all current Board Members proposed for re-election KPMG proposed for re-election as audi
Globe NewswireSimris Alg ab Signs Partnership Agreement With Lonza Ltd to Promote Its Adc Payload Technology
Strategic collaboration agreement to commercialize Simris’ novel Antibody-Drug Conjugate (ADC) payload platformSimris grants Lonza, as its Contract Development & Manufacturing Organization (CDMO) partner, the global exclusive rights to offer its ADC technology to biopharmaceutical companiesSimris will promote Lonza as its exclusive CDMO partner to customers interested in licensing its technology Stockholm, Sweden, March 06, 2023 (GLOBE NEWSWIRE) -- Simris Alg AB (publ), a European biologics comp
- EQS Group
Lonza Completes Expansion of Conjugation Facility in Visp (CH)
Lonza Group AG / Key word(s): ExpansionLonza Completes Expansion of Conjugation Facility in Visp (CH) 16.02.2023 / 14:00 CET/CEST Expansion adds development and manufacturing capacity for pre-clinical, clinical and commercial supply of bioconjugates and antibody-drug conjugates The Visp (CH) investment includes two manufacturing suites and supporting infrastructure Additional manufacturing suites complement recent investments in Visp (CH) across small molecules and biologics development and manu
- EQS Group
Lonza Prices CHF 300 Million Straight Bond with a 2.100% Coupon
Lonza Group AG / Key word(s): Bond/FinancingLonza Prices CHF 300 Million Straight Bond with a 2.100% Coupon 08.02.2023 / 18:30 CET/CESTBasel, Switzerland, 08 February 2023 – Lonza Swiss Finance Ltd, a wholly owned company of Lonza Group Ltd, Basel (“Lonza”), announced today the pricing of a CHF 300 million straight-bond issue in line with its financing plan for 2023. The bond has a maturity of 6.5 years and an annual coupon of 2.100%. The issuer is Lonza Swiss Finance Ltd, Basel, and the bond
- Simply Wall St.
Lonza Group Full Year 2022 Earnings: EPS Beats Expectations
Lonza Group ( VTX:LONN ) Full Year 2022 Results Key Financial Results Revenue: CHF6.22b (up 15% from FY 2021). Net...
ReutersEuropean stocks fall on earnings jitters, rate hike worries
(Reuters) -European stocks slipped on Wednesday as lacklustre results from U.S. software giant Microsoft fanned fears about the outlook for the tech sector, while investors remained concerned that central banks were not yet close to pausing their interest rate hikes. The pan-European STOXX 600 fell for a second day, closing down 0.3% but off a near two-week low hit earlier in the session. Technology shares, which have rebounded this year after a rough 2022, fell 0.4% as Microsoft forecast current-quarter cloud business revenue below estimates.
ReutersLonza to buy back $2.17 billion worth of shares, backs mid-term growth
(Reuters) -Lonza on Wednesday said it will buy back shares worth 2 billion Swiss francs ($2.17 billion), despite an expected drop in annual margins, as the Swiss drug contract manufacturer backed its growth prospects for the near future. Lonza expects its 2023 core earnings before interest, depreciation and amortization, or EBITDA margin, to slip between 30% and 31%, down from 32.1% in 2022, as last year's boost from COVID-19 vaccine manufacturing services waned. The firm, which is in a multi-year investment push to assist drug developers as they bet on new therapeutic proteins, as well as cell and gene therapies, also reported an almost 20% jump in core 2022 EBITDA of 2.0 billion Swiss francs, slightly ahead of market expectations.
EQS GroupLonza Delivers Strong 2022 Performance with 15.1% CER Sales Growth and 32.1% CORE EBITDA Margin
Lonza Group AG / Key word(s): Annual Results25-Jan-2023 / 07:00 CET/CESTRelease of an ad hoc announcement pursuant to Art. 53 LRThe issuer is solely responsible for the content of this announcement.Ad hoc announcement pursuant to Art. 53 LR In 2022, Lonza delivered CHF 6.2 billion sales and 15.1%1 CER sales growth CHF 2.0 billion CORE EBITDA resulted in a margin of 32.1% Growth investment continues as 2022 CAPEX reached 30% of sales Group Outlook 2023: high single-digit CER sales growth and CORE
- Simply Wall St.
Lonza Group AG's (VTX:LONN) Stock Has Shown Weakness Lately But Financial Prospects Look Decent: Is The Market Wrong?
With its stock down 9.8% over the past month, it is easy to disregard Lonza Group (VTX:LONN). However, stock prices are...
- Simply Wall St.
Institutions along with individual investors who hold considerable shares inLonza Group AG (VTX:LONN) come under pressure; lose 9.3% of holdings value
Every investor in Lonza Group AG ( VTX:LONN ) should be aware of the most powerful shareholder groups. We can see that...
- Simply Wall St.
With EPS Growth And More, Lonza Group (VTX:LONN) Makes An Interesting Case
It's common for many investors, especially those who are inexperienced, to buy shares in companies with a good story...
- Simply Wall St.
Lonza Group's (VTX:LONN) five-year total shareholder returns outpace the underlying earnings growth
It hasn't been the best quarter for Lonza Group AG ( VTX:LONN ) shareholders, since the share price has fallen 16% in...
- EQS Group
Lonza Launches New Capsule to Deliver Acid-Sensitive Active Pharmaceutical Ingredients to the Intestine
Lonza Group AG / Key word(s): Product LaunchLonza Launches New Capsule to Deliver Acid-Sensitive Active Pharmaceutical Ingredients to the Intestine 01.11.2022 / 07:00 CET/CEST Lonza meets pressing market need by launching first ever coating-free capsule to support intestinal delivery of acid-sensitive APIs Innovative Capsugel® Enprotect™ capsule can simplify the manufacturing process to accelerate drug development and expedite first-in-human timelinesBasel, Switzerland, 1 November 2022 – Lonza,
EQS GroupLonza Appoints Daniel Palmacci as President of the Cell & Gene Division
Lonza Group AG / Key word(s): PersonnelLonza Appoints Daniel Palmacci as President of the Cell & Gene Division 12.09.2022 / 07:00 CET/CEST Daniel Palmacci joins Lonza as President of the Cell & Gene Division and member of the Executive Committee Daniel will commence his tenure with Lonza Group on 1 November 2022, bringing deep industry knowledge, international experience and expertise in leading cross-functional teams Daniel takes over leadership of Cell & Gene from Jean-Christophe Hyvert, who w
- EQS Group
Lonza and Touchlight collaborate on end-to-end mRNA offering
Lonza Group AG / Key word(s): PartnershipLonza and Touchlight collaborate on end-to-end mRNA offering 06.09.2022 / 07:00 CET/CEST Collaboration expands Lonza’s end-to-end offering for mRNA manufacturing with additional, differentiated source of DNA raw material, Touchlight’s doggybone DNA (dbDNATM) Touchlight provides synthetic DNA through a cell-free enzymatic process, with advantages of speed, quality, capacity, and scalability Customers can gain access to Touchlight’s dbDNA as an integral par
ReutersLonza's first-half core EBITDA gains 16.5%
(Reuters) -Swiss drug contract manufacturer Lonza said first-half core earnings gained 16.5% on strong demand from biopharmaceutical companies. First-half core earnings - adjusted for interest, tax, depreciation and amortisation - (EBITDA) rose to 987 million Swiss francs ($1.02 billion), it said in a statement on Friday, beating an analyst consensus of about 940 million francs. For this year, Lonza said it was still targeting "low to mid-teens" sales growth, when excluding currency swings, as well as an improvement in the core EBITDA margin that is consistent with a 2024 goal of 33%-35%, up from 30.8% in 2021.
EQS GroupLonza Delivers Solid Performance in H1 2022 with 16.8% CER Sales Growth and 33.1% CORE EBITDA Margin
Lonza Group AG / Key word(s): Half Year Results22-Jul-2022 / 07:01 CET/CESTRelease of an ad hoc announcement pursuant to Art. 53 LRThe issuer is solely responsible for the content of this announcement.Ad hoc announcement pursuant to Art. 53 LR In H1 2022, Lonza delivers CHF 3 billion sales and 16.8%1 CER sales growth CHF 987 million CORE EBITDA resulted in a margin of 33.1% H1 2022 CAPEX reached 28.2% of sales as Lonza continues to execute planned investments Group Outlook 2022 confirmed at low